DK0652768T3 - Præparat til aktivering af naturlige dræberceller (NK-celler), hvilket præparat indeholder interferon-alfa og histamin, ser - Google Patents

Præparat til aktivering af naturlige dræberceller (NK-celler), hvilket præparat indeholder interferon-alfa og histamin, ser

Info

Publication number
DK0652768T3
DK0652768T3 DK93913731T DK93913731T DK0652768T3 DK 0652768 T3 DK0652768 T3 DK 0652768T3 DK 93913731 T DK93913731 T DK 93913731T DK 93913731 T DK93913731 T DK 93913731T DK 0652768 T3 DK0652768 T3 DK 0652768T3
Authority
DK
Denmark
Prior art keywords
cells
preparation
pct
histamine
alpha
Prior art date
Application number
DK93913731T
Other languages
Danish (da)
English (en)
Inventor
Kristoffer Hellstrand
Svante Hermodsson
Original Assignee
Maxim Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maxim Pharm Inc filed Critical Maxim Pharm Inc
Application granted granted Critical
Publication of DK0652768T3 publication Critical patent/DK0652768T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK93913731T 1992-06-03 1993-06-03 Præparat til aktivering af naturlige dræberceller (NK-celler), hvilket præparat indeholder interferon-alfa og histamin, ser DK0652768T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9201719A SE513429C2 (sv) 1992-06-03 1992-06-03 Preparat för aktivering av naturliga mördarceller, vilket preparat innehåller interferon alfa och biogena aminer
PCT/SE1993/000496 WO1993024144A1 (en) 1992-06-03 1993-06-03 PREPARATION FOR ACTIVATION OF NATURAL KILLER CELLS (NK-CELLS), SAID PREPARATION CONTAINING INTERFERON-α AND HISTAMINE, SEROTONIN OR SUBSTANCES WITH CORRESPONDING RECEPTOR ACTIVITY

Publications (1)

Publication Number Publication Date
DK0652768T3 true DK0652768T3 (da) 2000-08-07

Family

ID=20386405

Family Applications (1)

Application Number Title Priority Date Filing Date
DK93913731T DK0652768T3 (da) 1992-06-03 1993-06-03 Præparat til aktivering af naturlige dræberceller (NK-celler), hvilket præparat indeholder interferon-alfa og histamin, ser

Country Status (12)

Country Link
US (1) US5728378A (sv)
EP (1) EP0652768B1 (sv)
JP (1) JP2888259B2 (sv)
AT (1) ATE192338T1 (sv)
CA (1) CA2136952C (sv)
DE (1) DE69328558T2 (sv)
DK (1) DK0652768T3 (sv)
ES (1) ES2147758T3 (sv)
GR (1) GR3033894T3 (sv)
PT (1) PT652768E (sv)
SE (1) SE513429C2 (sv)
WO (1) WO1993024144A1 (sv)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6063373A (en) 1989-09-19 2000-05-16 Maxim Pharmaceuticals, Inc. Enhanced activation of NK cells using an NK cell activator and a hydrogen peroxide scavenger or inhibitor
US6003516A (en) * 1992-06-03 1999-12-21 Maxim Pharmaceuticals, Inc. Method for treatment of cancer and infectious disease
EP0690715B1 (en) * 1993-03-26 2003-05-28 Beth Israel Hospital Association Topical and systemic application of buspirone or derivatives thereof for treatment of pathological conditions associated with immune responses
JPH10504304A (ja) * 1994-08-08 1998-04-28 マキシム ファーマシューティカルズ，インコーポレイテッド ナチュラルキラー細胞活性化物質と過酸化水素スカベンジャーまたは過酸化水素阻害物質とを用いるナチュラルキラー細胞の活性増強
US6071942A (en) 1996-05-14 2000-06-06 Maxim Pharmaceuticals, Inc. Elevation of circulating blood histamine levels
US5961969A (en) * 1996-05-14 1999-10-05 Maxim Pharmaceuticals, Inc. Stable circulating histamine levels
AU778012B2 (en) * 1996-05-14 2004-11-11 Maxim Pharmaceuticals, Inc. Administration of histamine for therapeutic purposes
WO2000010600A2 (en) * 1998-08-24 2000-03-02 Maxim Pharmaceuticals, Inc. Activation and protection of t-cells (cd4+ and cd8+) using an h¿2? receptor agonist and other t-cell activating agents
EP0998923A1 (en) * 1998-10-30 2000-05-10 Basf Aktiengesellschaft Use of 5-HT7 receptor agonists for the treatment or prophylaxis of ischemias
DE69939027D1 (de) 1998-12-23 2008-08-14 Maxim Pharm Inc Synthese von histamin-dihydrochlorid
US6498181B1 (en) * 1999-01-06 2002-12-24 Maxim Pharmaceuticals Synergistic tumorcidal response induced by histamine
US6242473B1 (en) 1999-01-08 2001-06-05 Maxim Pharmaceuticals, Inc. Treatment and prevention of reactive oxygen metabolite-mediated cellular damage
US6153113A (en) * 1999-02-22 2000-11-28 Cobe Laboratories, Inc. Method for using ligands in particle separation
US6354986B1 (en) 2000-02-16 2002-03-12 Gambro, Inc. Reverse-flow chamber purging during centrifugal separation
DE10053397A1 (de) 2000-10-20 2002-05-02 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
DE10043321B4 (de) * 2000-08-24 2005-07-28 Neurobiotec Gmbh Verwendung eines transdermalen therapeutischen Systems zur Behandlung der Parkinsonschen Krankheit, zur Behandlung und Prävention des prämenstruellen Syndroms und zur Lactationshemmung
DE10064453A1 (de) * 2000-12-16 2002-07-04 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
KR20040058192A (ko) * 2001-10-19 2004-07-03 맥심 파마수티컬즈 인크. 간 질환 치료용으로서의 히스타민 용도
CN100563648C (zh) * 2003-04-25 2009-12-02 田边三菱制药株式会社 包含亚烷基二氧苯衍生物的口服组合物
US20050171192A1 (en) * 2003-12-11 2005-08-04 Gehlsen Kurt R. Use of histamine to treat bone disease
US20060002913A1 (en) * 2004-06-22 2006-01-05 Gehlsen Kurt R Use of histamine and related compounds to treat disorders affecting muscle function
EP1712634A1 (en) * 2005-04-13 2006-10-18 Wittycell SAS Selection of highly efficient antigen presenting cells for regulating immunity and uses thereof
SG166716A1 (en) 2009-05-14 2010-12-29 Hsiehs Biotech Singapore Pte Ltd Lycopene and resveratrol compositions for nk cell activation resulting in anti-neoplastic effect
WO2014130759A1 (en) * 2013-02-21 2014-08-28 University Of Rochester Methods of using histamine receptor agonists and antagonists
CN115925920B (zh) * 2022-08-04 2023-07-25 瑞因细胞工程科技(广州)有限公司 一种基因增强型免疫细胞治疗肝硬化的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4863727A (en) * 1986-04-09 1989-09-05 Cetus Corporation Combination therapy using interleukin-2 and tumor necrosis factor
US5215744A (en) * 1987-06-16 1993-06-01 Boehringer Ingelheim Gmbh Methods for the treatment of tumors
EP0295317A1 (en) * 1987-06-16 1988-12-21 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Pharmaceutical composition for the treatment of tumors
US4883661A (en) * 1987-10-09 1989-11-28 Daly John M Use of arginine as an lymphokine synergist
US5026544A (en) * 1988-02-16 1991-06-25 Board Of Reagents, The University Of Texas System Methods and compositions for inhibiting the growth of neoplastic cells

Also Published As

Publication number Publication date
ES2147758T3 (es) 2000-10-01
AU672610B2 (en) 1996-10-10
SE9201719L (sv) 1993-12-04
JPH08502024A (ja) 1996-03-05
DE69328558D1 (de) 2000-06-08
WO1993024144A1 (en) 1993-12-09
DE69328558T2 (de) 2001-01-04
ATE192338T1 (de) 2000-05-15
PT652768E (pt) 2000-09-29
AU4366093A (en) 1993-12-30
US5728378A (en) 1998-03-17
CA2136952A1 (en) 1993-12-09
EP0652768B1 (en) 2000-05-03
CA2136952C (en) 2005-08-09
JP2888259B2 (ja) 1999-05-10
SE513429C2 (sv) 2000-09-11
SE9201719D0 (sv) 1992-06-03
GR3033894T3 (en) 2000-11-30
EP0652768A1 (en) 1995-05-17

Similar Documents

Publication Publication Date Title
DK0652768T3 (da) Præparat til aktivering af naturlige dræberceller (NK-celler), hvilket præparat indeholder interferon-alfa og histamin, ser
BR9912975A (pt) Composto e composições para liberação de agentes ativos, método para sua obtenção e seu uso
TR200101398T2 (tr) Pirolidin türevleri-CCR-3 reseptörü antagonistleri.
BR0016227A (pt) Derivados de adamantano
HUT73807A (en) 5-ht1-like indole derivatives and pharmaceutical compositions containing them
DE59406938D1 (de) Pharmazeutische zubereitungen mit einem wirkstoff, der modifizierte amidingruppen enthält
YU47116B (sh) Postupak za dobijanje novih n-supstituisanih benzimidazolskih derivata
DE69724438D1 (de) Nicht peptidische g-csf mimetika
BR9306345A (pt) Métodos para suprimir a habilidade de células-t de um mamífero de proliferar e para suprimir resposta imune composições para uso na supressão da capacidade de células-t de proliferarem e na supressão de resposta imune
DK0614362T3 (da) Farmaceutiske præparater på basis af ebastin og dermed analoge forbindelser
DK0639275T3 (da) Hidtil ukendte GABAa-receptorundertyper og fremgangsmåder til screening af lægemiddelforbindelser under anvendelse af imidazoquinoxaliner og pyrrolopyimidiner til binding til GABAa-receptorundertyper
ES2131528T3 (es) Nuevos polipeptidos y su uso.
ES2104133T3 (es) Composiciones cosmeticas o farmaceuticas que contienen glicerofosfolipidos desacilados para uso topico.
HK1019010A1 (en) Preparation of n-acetyl neuraminic derivatives
NO944214D0 (no) Farmasöytiske preparater for rektal administrering, inneholdende alkylsulfonamider som er HT1-agonister
ATE348604T1 (de) Agonisten und antagonisten der nicotinergen acetylcholinrezeptoren von insekten als endoparasitizide
ES2156444T3 (es) Nuevos compuestos.
NZ234451A (en) Benzofuran-substituted 2-imidazoline derivatives and pharmaceutical compositions
ATE169021T1 (de) Cephalostatin-analoga und ihre verwendung als antitumormittel
MX9303607A (es) Derivados de azabicicloheptano sustituidos, su obtencion y uso.
ES2052499T3 (es) Complejos de (gem-heterociclodimenatamina-n,n') platino.
YU46750B (sh) Derivati laktama i postupci za njihovo dobijanje
SU1625237A1 (ru) Парафиновая композиция для субтитрирования фильмокопий